HROW earnings

Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Cash and cash equivalents of $72.9 million as of December 31, 2025Full-year 2026 revenue guidance of $350 million to $365 million, including $133 million to $153 million in the first half of

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 3, 2026, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on

Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Inve

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on t

Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s

NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'

First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 28, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, March 28, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live co

Company Expects to Provide Revised Dates for Release of Audited Financial Results, Conference Call, and Letter to Stockholders Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company's new independent auditor requires additional time to audit Harrow's financial presentation. As a result, Harrow is delaying its earnings release, conference call and Annual Report on Form 10-K filing. The change in the date of the filing of

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 18, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2024, on Monday, March 17, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, March 18, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen

Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8 million Operating cash flow of $3 million Cash and cash equivalents of $72.6 million as of September 30, 2024 VEVYE® total prescriptions up 55% over the second quarter of 2024 IHEEZO® customer unit demand volume up 15% over the second quarter of 2024 TRIESENCE® October 2024 relaunch underway Expansion of access and affordability through multiple new partnerships First major Medicare Part D win for VEVYE with major plan sponsors Fourth quarter revenue indicates meaningfu

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen

Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast

First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedures, retroactive to January 1, 2024. Recently signed IHEEZO supply agreements with seven multi-practice strategic accounts. U.S. Patent and Trademark Office recently granted new IHEEZO patent claims with an expiry through 2039. Sequential month-over-month growth in VEVYE total prescriptions, new prescriptions, prescribers, and refills. Covered lives fo

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update. Conference Call Details:      Date:   Tuesday, May 14, 2024 Time:   8:00 a.m. Ea

Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of $13.0 million. Cash from operating activities of $3.8 million. GAAP gross margin was 70% compared with 71% in the prior-year period. Core gross margin was 77% compared with 73% in the prior-year period. Cash and cash equivalents of $83 million, including investments in Eton Pharmaceuticals, as of December 31, 2023. Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, annou

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update. Conference Call Details:   Date: Wednesday, March 20, 2

Third Quarter 2023 and Recent Selected Highlights: Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase of 2% over $33.5 million in the sequential quarter. GAAP net loss of $(4.4 million). Adjusted EBITDA of $9.2 million, an increase of 270% over $2.5 million in the prior‑year quarter. GAAP gross margin was flat at 71%, year-over-year. Core gross margin improved to 78% over the prior year's 72%. Cash and cash equivalents of $65.6 million as of September 30, 2023. Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. Harrow (NASDAQ:HROW), a leadi

Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Monday, November 13, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)

Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter ended June 30, 2023, on Wednesday, August 9, 2023, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details: Date: Wednesday, August 9, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)

First Quarter 2023 and Recent Selected Highlights: Record revenues of $26.1 million, up 18% over $22.1 million for the prior-year quarter and 28% over sequential quarter revenues of $20.3 million. Completed transfer of New Drug Applications (NDAs) for ILEVRO®, NEVANAC®, and MAXIDEX®. Signed an agreement with a large health insurance carrier to provide ImprimisRx's atropine.com and Klarity-C compounded formulations on a cash-pay basis to its national vision care network. Successfully launched FDA-approved IHEEZO™ at the American Society of Cataract and Refractive Surgery ("ASCRS") annual meeting held between May 5-8, 2023. Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceu

Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Thursday, May 11, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)

2022 and Recent Highlights: Full-year 2022 revenues of $88.6 million, up 22% over full-year 2021 revenues of $72.5 million Sold all non-ophthalmology assets, making Harrow a pure-play ophthalmic pharmaceutical company FDA approval of IHEEZO™ topical ocular anesthetic CMS issuance of Permanent J-Code (J2403) and Pass-Through Reimbursement Status for IHEEZO Acquired U.S. commercial rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® Launched Fortisite™ fortified antibiotic compounded formulations Launched preservative-free and boric-acid free compounded atropine.com™ formulations Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced r

Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2022, on Thursday, March 23, 2023, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Thursday, March 23, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International) Replay Di

Selected Recent Highlights: FDA approval of IHEEZO™ for ocular surface anesthesia Launch of Fortisite™, fortified antibiotics Launch of atropine.com™ compounded atropine portal Revenues of $22.8 million, up 22% over $18.7 million for the prior‑year quarter Nearly $1 million firm order revenue backlog at September 30, 2022 Product units shipped of 703,000, up 21% from prior-year quarter Cash and cash equivalents of $45.0 million as of September 30, 2022 Harrow (NASDAQ:HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced results for the third quarter ended September

Harrow (NASDAQ:HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Monday, November 14, 2022 Time: 4:45 p.m. Eastern time

Revenues Increase for Eighth Consecutive Quarter Highlights for Second Quarter 2022: Record revenues of $23.3 million, up 29% over $18.1 million for the prior‑year quarter Record gross profit of $16.8 million, up 22% over $13.7 million for the prior‑year quarter A record 718,000 product units shipped, up 4% from the prior-year quarter Cash and cash equivalents of $46.4 million as of June 30, 2022 Harrow Health, Inc. (NASDAQ:HROW), an eyecare pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medicines, today announced results for the second quarter ended June 30, 2022. The Company also posted its second quar

Harrow Health, Inc. (NASDAQ:HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for the second quarter ended June 30, 2022, on Tuesday, August 9, 2022, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Tuesday, A

Seventh Consecutive Quarter of Record Results Highlights for First Quarter 2022: Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year quarter Record gross profit of $16.2 million, up 38% over $11.7 million for the prior-year quarter Record number of 689,000 product units shipped, up 72% from the prior-year quarter Cash and cash equivalents of $42.0 million as of March 31, 2022 Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced results for the first quarter ended March 31, 2022. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, ha

Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Thursday, May 5, 2022 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International) Replay Dial

Sixth Consecutive Quarter of Record Revenues  Highlights for Fourth Quarter 2021: Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prior‑year quarter; Gross profit was a record $15.1 million, a 42% increase compared with $10.7 million for the prior‑year quarter; Gross margin increased to 75% compared with 73% in the prior-year quarter; FDA acceptance of AMP-100 NDA and assignment of PDUFA target date of October 16, 2022; Commissions from DEXYCU® sales increased to $1.0 million on record unit volumes; and Cash and cash equivalents was $42.2 million at December 31, 2021. Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare comp

Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2021, on Thursday, March 10, 2022, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Thursday, March 10, 2022 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (Internation

Revenues Reach Record Levels for Fifth Consecutive Quarter   Highlights for Third Quarter 2021: Record revenues of $18.7 million, a 30% increase compared with $14.4 million for the prior-year period; Gross margin of 74% consistent with prior-year period; Acquired AMP-100 late-stage ophthalmic surgical drug candidate for FDA-approval; Acquired MAQ-100 ophthalmic surgical drug candidate for FDA-approval; Commissions from DEXYCU® sales increased to $900,000 on record unit volumes; and Cash and cash equivalents was $57.9 million at September 30, 2021. Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, today announced results for the third quarter and ni

Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details:   Date: Tuesday, November 9, 2021 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763

Fourth Consecutive Quarter of Record Results Highlights for Second Quarter 2021: Record revenues of $18.1 million, a 125% increase compared with $8.1 million for the prior-year period; Gross margin was 75.6%, compared with 60.2% for the prior-year period; GAAP operating income increased to $4.2 million compared with an operating loss of $3.2 million for the prior-year period; Commissions from DEXYCU® sales increased to $827,000 on record unit volumes; and Cash and cash equivalents was $72.9 million at June 30, 2021. Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June 30, 202

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ:HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details: Date:Tuesday, August 10, 2021Time:4:45 p.m. Eastern timeParticipant Dial-in:1-833-953-2434 (U.S.)1-412-317-